Lilly's Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo's Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and Deals
Ottawa, Nov. 16, 2026 (GLOBE NEWSWIRE) -- 
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and is projected to reach USD 64.96 billion by 2035 at a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate, while Pfizer , Roche , Amgen and a group of emerging developers are investing to win share in the Next wave of therapies.

Precedence Research today released updated company intelligence on the global anti-obesity drugs market, focusing on the companies that lead it and the investments, pipelines and deals that will decide its future. The market is valued at USD 8.96 billion in 2026 and is forecast to reach USD 64.96 billion by 2035.
Two companies set the pace. Eli Lilly's third-quarter 2026 revenue rose 39% to USD 24.4 billion, with Mounjaro at USD 10.7 billion and Zepbound at USD 5.4 billion, and its oral GLP-1 Foundayo, approved on April 1, 2026, has started to add sales. Novo Nordisk 's obesity sales rose 22% at constant exchange rates to DKK 26.1 billion, helped by the Wegovy pill launched in the U.S. in January 2026. Both companies raised their 2026 outlooks.
Challengers are investing heavily to catch up. Pfizer completed its acquisition of Metsera for up to USD 10 billion, Roche signed a USD 5.3 billion collaboration with Zealand Pharma , and Amgen has started Phase 3 trials of MariTide. Meanwhile, the leaders are building new pipelines and plants: Lilly's retatrutide delivered up to 22.6% weight loss in Phase 3, Novo has filed CagriSema with the FDA, and Lilly is investing USD 50 billion in U.S. manufacturing. This release profiles the top companies and what their moves mean for competition through 2035.
Full report: https://www.precedenceresearch.com/anti-obesity-drugs-market
Request a sample: https://www.precedenceresearch.com/sample/4896
Market at a Glance
| Market Indicator | Value |
| Market size, 2025 → 2026 | USD 7.14 billion → USD 8.96 billion |
| Market size, 2035 | USD 64.96 billion |
| CAGR, 2026–2035 | 24.71% |
| U.S. market, 2025 → 2035 | USD 3.59 billion → around USD 33.17 billion (24.90% CAGR) |
| Largest region / fastest-growing region | North America (more than 67%) / Asia Pacific |
| Largest type / leading channel | Prescription drugs (92%) / retail & online pharmacy |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Figure 1: Anti-Obesity Drugs Market Snapshot
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Prescription GLP-1 and dual-agonist therapies make up almost all revenue, and North America accounts for more than two-thirds of it. Asia Pacific is the fastest-growing region as Lilly, Novo Nordisk and regional developers such as Innovent, LG Chem and Zydus expand there.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Top Companies in the Anti-Obesity Drugs Market

Figure 2: Top Anti-Obesity Drug Companies, Latest Results (Q3 2026)
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
| Company | Key Products / Assets | Latest Reported Data | Position |
| Eli Lilly | Zepbound, Mounjaro (tirzepatide), Foundayo (orforglipron), retatrutide | Q3 2026 revenue USD 24.4B (+39%); Mounjaro USD 10.7B (+65%); Zepbound USD 5.4B (+49%); Foundayo USD 184M | Market leader; 2026 revenue guidance raised to USD 91–92B |
| Novo Nordisk | Wegovy injection, Wegovy pill, CagriSema | Q3 2026 obesity sales DKK 26.1B (+22% CER); Wegovy pill DKK 5.4B; Wegovy injection DKK 20.4B (-2% CER) | No. 2; pill launched in 8 markets; outlook raised Nov 4, 2026 |
| Pfizer | Metsera pipeline | Acquisition completed Nov 2025 (up to USD 10B) | Re-entering obesity with long-acting injectables |
| Roche | Zealand Pharma collaboration | USD 5.3B deal (May 2025) | Building an Amylin -based franchise |
| Amgen | MariTide | Phase 3 program launched, including a 1,200-patient switch study (May 2026) | Targets less frequent dosing |
| Astrazeneca / Boehringer Ingelheim | Clinical-stage candidates | Named key players in the report | Next -generation mechanisms |
| Rhythm Pharmaceuticals | Setmelanotide | Rare genetic obesity | Niche specialist |
| Innovent / LG Chem / Zydus | Regional candidates | Named key players in the report | Asia Pacific challengers |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Lilly and Novo Nordisk hold a lead that other companies will struggle to close before the end of the decade. Lilly is growing faster, with tirzepatide sales rising in every region AND Int. Mounjaro revenue up 93% in the third quarter. Novo Nordisk is shifting its growth to the Wegovy pill, which recorded about 3.6 million prescriptions in the quarter and more than 8 million since launch, while injectable Wegovy sales were slightly lower.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Company Pipelines: The Next Generation of Obesity Drugs
| Company | Candidate | Mechanism / Format | Latest Milestone |
| Eli Lilly | Retatrutide | Triple agonist (GIP, GLP-1, glucagon), weekly injection | Phase 3 TRIUMPH-3: 21.6–22.6% weight loss at 80 weeks; FDA filing planned Q1 2027 |
| Eli Lilly | Foundayo (orforglipron) | Oral small-molecule GLP-1, no food or water restrictions | FDA approved April 1, 2026; Q3 sales USD 184M |
| Novo Nordisk | CagriSema | GLP-1 plus Amylin , weekly injection | Filed with FDA Dec 2025; 22.7% weight loss in REDEFINE 1 |
| Novo Nordisk | Wegovy pill | Oral semaglutide | U.S. launch Jan 5, 2026; DKK 10.9B in 9M 2026 sales |
| Amgen | MariTide | Long-acting GLP-1 antibody-peptide | Phase 3 trials started (2026) |
| Pfizer | Metsera assets | Long-acting injectables | Acquired Nov 2025 |
| Roche / Zealand | Petrelintide program | Amylin analogue | USD 5.3B collaboration (May 2025) |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
The pipeline shows where competition is heading: higher weight loss (retatrutide and CagriSema at more than 20%), pills that are easier to take and to manufacture, and longer dosing intervals. Companies that combine strong efficacy with convenient formats and manufacturing scale will capture the most share.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Company Investments and Deals

Figure 3: Company Investments and Deals in Obesity
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
These investments show that manufacturing capacity and access to new mechanisms are now the main competitive levers. Building peptide and oral manufacturing capacity takes years, which protects the leaders but also creates opportunities for contract manufacturers and device suppliers.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Key Company Developments

Figure 4: Top Company Moves in Anti-Obesity Drugs, 2025–2026
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Pills are changing the market. Novo's Wegovy pill launched in the U.S. on January 5, 2026, at self-pay prices of USD 149–299 a month and is available at more than 70,000 pharmacies. Lilly's Foundayo was approved on April 1, 2026, as the first daily GLP-1 pill without food or water restrictions.
What it indicates: Oral drugs widen access in primary care and emerging markets, and the competition between the two leaders is moving from injections to pills.
Prices are falling as volumes rise. Pricing agreements announced in November 2025 opened Medicare coverage for eligible patients and set prices around USD 245 a month for government programs.
What it indicates: Revenue growth will come from more patients rather than higher prices, rewarding the companies with the largest supply.
Late-stage data are raising the bar. Lilly reported in July 2026 that retatrutide produced up to 22.6% weight loss at 80 weeks in TRIUMPH-3, and Novo's CagriSema showed 22.7% weight loss in REDEFINE 1.
What it indicates: New entrants will need to match more than 20% weight loss or offer clear advantages in dosing, tolerability or cost.
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Key Market Drivers
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Major Challenges
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Emerging Opportunities
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Company Ecosystem

Figure 5: Anti-Obesity Drugs Company Ecosystem, 2026
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
The supply side combines the two market leaders, large pharmaceutical challengers, emerging developers such as Viking Therapeutics, Structure Therapeutics and Terns, and a manufacturing base that includes Novo Holdings' Catalent, Thermo Fisher, Lonza and device makers. The demand side includes pharmacies and telehealth platforms, payers and PBMs, employers and care providers.
Customer and Buyer Intelligence
| Target Account Group | Decision-Makers | Purchase Signals | Commercial Opportunity |
| Pharma business development | Head of BD, Metabolic R&D Head | Pipeline gaps, competitor data | In-licensing and acquisitions |
| Employers | CHRO, Benefits Director | Rising GLP-1 claims | Managed coverage programs |
| Health plans and PBMs | Chief Pharmacy Officer | Price agreements, oral launches | Formulary and utilization contracts |
| Pharmacies and telehealth | Category and Operations Heads | Self-pay demand for pills | Direct-to-consumer fulfillment |
| CDMOs and device makers | BD and Operations Heads | Plant announcements | Peptide, oral and pen supply |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
How Precedence Research Supports Decision-Making
Master Dataset provides company, segment and regional data for obesity drugs and adjacent markets such as the anti-obesity medication, pharmaceutical and pharmacy markets. It helps teams size each company's position by product and region.
Precedence Quadrant ranks obesity drug companies on sales, pipeline strength, manufacturing scale and access, helping business development teams and investors screen leaders and challengers.
Interactive Intelligence Dashboard tracks company results, approvals, trial readouts, price changes and deals, so teams can respond to competitor moves quickly.
Quality & Manufacturing Intelligence maps company and CDMO capacity for peptides, oral products and devices, supporting supply and partnering decisions.
Customized Research answers specific questions, such as competitor benchmarking, pill versus injection uptake or partner screening in Asia Pacific.
| Solution | What It Provides | How It Helps |
| Master Dataset | Company, segment and region data on obesity drugs | Sizes each company's position |
| Precedence Quadrant | Ranking of leaders and challengers | Screens partners and acquisition targets |
| Interactive Dashboard | Live tracking of results, approvals and deals | Times competitive responses |
| Quality & Manufacturing Intelligence | Company and CDMO capacity mapping | Supports supply and partnering |
| Customized Research | Benchmarking and uptake studies | Answers decision-specific questions |
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Why Continuously Updated Intelligence Matters
The competitive picture in obesity changes every quarter. Monthly updates suit teams tracking prescriptions, prices and launches. Quarterly updates match Lilly and Novo Nordisk earnings. Six-monthly updates follow trial readouts and FDA decisions such as CagriSema and retatrutide, and annual updates support investors reviewing company share and market size. Precedence Research offers all four update cycles.
Strategic Outlook
Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher
Call to Action
To compare the top anti-obesity drug companies and track their Next moves, explore the full report or speak with a Precedence Research analyst.
Fill out the form for relevant samples, case studies, and examples. sales@precedenceresearch.com
Related Reports
About Precedence Research
Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, consumer health, ICT , energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.
Our Partners
Connect Group With Us
Social Media